Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells

Lock, Kevin; Zhang, Jiquan; Lu, Jinhua; Lee, Szu Hee; Crocker, Paul R.

doi:10.1016/j.imbio.2004.04.007

Cited by 114 publications

(82 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Siglec-9 is expressed on neutrophils, monocytes/macrophages, and dendritic cells (30,31). The microenvironment of solid tumors is characterized by a reactive stroma with an abundance of inflammatory mediators and leukocytes.…”

Section: Discussionmentioning

confidence: 99%

Binding of the Sialic Acid-binding Lectin, Siglec-9, to the Membrane Mucin, MUC1, Induces Recruitment of β-Catenin and Subsequent Cell Growth

Tanida

Akita

Ishida

et al. 2013

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: MUC1 plays a role in mediation of signaling initiated by growth factors. Results: Siglec-9-positive cells are associated with MUC1-positive tumor cells in tumor tissues, and Siglec-9 binds to MUC1. Conclusion: MUC1-mediated signaling occurs by direct binding of Siglec-9 to MUC1. Significance: Multiple signaling pathway through MUC1 can be advantageous to adjust to various conditions of tumor microenvironments.

show abstract

Section: Discussionmentioning

confidence: 99%

Binding of the Sialic Acid-binding Lectin, Siglec-9, to the Membrane Mucin, MUC1, Induces Recruitment of β-Catenin and Subsequent Cell Growth

Tanida

Akita

Ishida

et al. 2013

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…+ populations present in circulating monocytes, 36 with 96-97% purity of monocytes in each group. The expression of CD29 on monocytes in patients with active chronic GVHD was significantly greater than that in patients with no or inactive chronic GVHD ( Figure 3B).…”

Section: Increased Cd29mentioning

confidence: 99%

Interleukin-10 spot-forming cells as a novel biomarker of chronic graft-versus-host disease

et al. 2012

View full text Add to dashboard Cite

ABSTRACTcytokine SFC in patients following HSCT and correlated the results with clinical findings. Furthermore, expression of CD29 (b1 integrin) on monocytes was correlated with plasma levels of fibronectin in patients with active chronic GVHD. Design and Methods PatientsFifty-seven patients who underwent allogeneic HSCT between 1995 and 2009 were included in this study. The patients' demographic data are shown in Table 1. Sixteen patients with chronic GVHD were grouped into mild (n=7), moderate (n=8), and severe (n=1) categories based on the NIH chronic GVHD consensus criteria. 5 According to Sarantopoulos's definition of chronic GVHD activity, patients were subclassified into those with no, active, and inactive chronic GVHD. 28 Patients who never developed chronic GVHD (n=41) were designated as "no chronic GVHD". Patients with active chronic GVHD (n=14) were more likely to be receiving immunosuppressive therapy. Inactive chronic GVHD (n=10) was determined by clinical assessment and included patients who had achieved a complete response to immunosuppressive therapy at the time of analysis. The number of patients with active and inactive chronic GVHD overlapped during the clinical course. Disease activity was assessed without knowledge of the laboratory results. The median time of the analysis was 48 (range, 4-204), 52 (5-142), and 55 (4-151) months after transplantation for patients with no, active, and inactive chronic GVHD, respectively.This study was conducted according to the principles expressed in the Declaration of Helsinki and approved by the Institutional Ethics Committee Review Board at Mie University Hospital. The study was registered with the national regulatory authority (UMIN-Clinical Trials Registry). All participants or their guardians provided written informed consent for the collection of samples and subsequent analyses. Diagnosis of chronic graft-versus-host disease and processing of samplesThe diagnosis of chronic GVHD requires the presence of at least one diagnostic manifestation of the disease or at least one distinctive manifestation, with the diagnosis confirmed by pertinent biopsy, laboratory tests, or radiology in the same or another organ.5,29 Diagnostic manifestations of chronic GVHD were found in the skin, nails, mouth, eyes, lungs, gastrointestinal tract, and liver. The grade of chronic GVHD was determined according to NIH consensus criteria. 5,30 Peripheral blood mononuclear cells (PBMC) were obtained from patients with no evidence of infection, and the diagnoses were confirmed by laboratory testing or radiology, at least 100 days after allogeneic HSCT. The total numbers of white blood cells, lymphocytes, and monocytes were analyzed by an automatic blood cell counter (Sysmex K4500, Toa Medical Electronics, Tokyo, Japan). Flow cytometry and cell separationCells were stained with fluorescein-conjugated monoclonal antibodies to human anti-CD3, CD4, CD8, CD11c, CD16, CD19, CD25, CD29, CD33, CD56, CD123 (BD Biosciences, San Jose, CA, USA), CD14 (Beckman Coulter, CA, USA), CD68, interle...

show abstract

“…Antigen ligation of the BCR results in mobilization of the BCR to "activation rafts," which subsequently fuse with clathrin domains prior to endocytosis (69, 70). Since CD22 is specifically excluded from activation rafts (54), the negative regulatory effect of CD22 on BCR signaling has been proposed to occur following its movement to clathrin domains (23), linking the endocytic activity of CD22 to its role in regulation of BCR signaling.Sn and most CD33-related siglec proteins are expressed on cells of the innate immune system, including monocytes, macrophages, neutrophils, eosinophils, and dendritic cells (25,43,50,85), focusing investigations into their precise functions on the known activities of these cells. Like CD22, ligation of CD33-related siglec proteins (CD33 and Siglec-5, -7, and -9) also induces recruitment of SHP-1 via phosphorylated ITIMs (6, 7, 53, 72).…”

mentioning

confidence: 99%

“…The others comprise a rapidly evolving subfamily homologous to CD33/Siglec-4, known as the CD33-related siglec proteins. With two exceptions (MAG and Siglec-6) the siglec proteins are predominantly expressed in various white blood cells of the immune system (25,43,78,85). All contain a N-terminal V-set sugar-binding Ig domain, a variable number of additional C-set Ig domains, a transmembrane domain, and a cytoplasmic domain that typically contains tyrosine-based motifs implicated in regulation of cell signaling and endocytosis.…”

mentioning

confidence: 99%

Distinct Endocytic Mechanisms of CD22 (Siglec-2) and Siglec-F Reflect Roles in Cell Signaling and Innate Immunity

Tateno

Schur

et al. 2007

Molecular and Cellular Biology

Self Cite

116

109

View full text Add to dashboard Cite

Sialic acid-binding immunoglobulin-like lectins (siglecs) are predominately expressed on immune cells. They are best known as regulators of cell signaling mediated by cytoplasmic tyrosine motifs and are increasingly recognized as receptors for pathogens that bear sialic acid-containing glycans. Most siglec proteins undergo endocytosis, an activity tied to their roles in cell signaling and innate immunity. Here, we investigate the endocytic pathways of two siglec proteins, CD22 (Siglec-2), a regulator of B-cell signaling, and mouse eosinophil Siglec-F, a member of the rapidly evolving CD33-related siglec subfamily that are expressed on cells of the innate immune system. CD22 exhibits hallmarks of clathrin-mediated endocytosis and traffics to recycling compartments, consistent with previous reports demonstrating its localization to clathrin domains. Like CD22, Siglec-F mediates endocytosis of anti-Siglec-F and sialoside ligands, a function requiring intact tyrosinebased motifs. In contrast, however, we find that Siglec-F endocytosis is clathrin and dynamin independent, requires ADP ribosylation factor 6, and traffics to lysosomes. The results suggest that these two siglec proteins have evolved distinct endocytic mechanisms consistent with roles in cell signaling and innate immunity.The siglec (sialic-acid binding immunoglobulin [Ig]-like lectins) proteins are subset of the Ig superfamily of cell recognition molecules that bind to sialic acid-containing glycans of cell surface glycoconjugates as ligands (27,78). Of the 13 human and 9 murine siglec proteins, 4 are highly conserved in mammalian species: sialoadhesin (Sn)/Siglec-1, CD22/Siglec-2, myelin-associated glycoprotein (MAG)/Siglec-4, and Siglec-15. The others comprise a rapidly evolving subfamily homologous to CD33/Siglec-4, known as the CD33-related siglec proteins. With two exceptions (MAG and Siglec-6) the siglec proteins are predominantly expressed in various white blood cells of the immune system (25,43,78,85). All contain a N-terminal V-set sugar-binding Ig domain, a variable number of additional C-set Ig domains, a transmembrane domain, and a cytoplasmic domain that typically contains tyrosine-based motifs implicated in regulation of cell signaling and endocytosis.Many of the siglec proteins contain one or more immunoreceptor tyrosine-based inhibitory motifs (ITIMs), (I/L/V)XYXX (L/V), suggesting that they play important roles as inhibitory receptors of cell signaling (25, 78), as exemplified by CD22, which is well documented as a regulator of B-cell receptor (BCR) signaling. Upon antigen binding to the BCR, the ITIMs of CD22 are quickly tyrosine phosphorylated and recruit protein tyrosine phosphatase SHP-1, which dephosphorylates the BCR and dampens the B-cell response, setting a threshold for B-cell activation (27,73).CD22 is also known to undergo endocytosis following ligation by anti-CD22 antibody (38, 64) or high-affinity multivalent-sialoside ligands (22). The tyrosine-based ITIMs of CD22 also fit the sorting signal YXXØ (where Ø is a hydrophobic...

show abstract

Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells

Cited by 114 publications

References 46 publications

Binding of the Sialic Acid-binding Lectin, Siglec-9, to the Membrane Mucin, MUC1, Induces Recruitment of β-Catenin and Subsequent Cell Growth

Binding of the Sialic Acid-binding Lectin, Siglec-9, to the Membrane Mucin, MUC1, Induces Recruitment of β-Catenin and Subsequent Cell Growth

Interleukin-10 spot-forming cells as a novel biomarker of chronic graft-versus-host disease

Distinct Endocytic Mechanisms of CD22 (Siglec-2) and Siglec-F Reflect Roles in Cell Signaling and Innate Immunity

Contact Info

Product

Resources

About